Patent ductus arteriosus in preterm infants

Area of Science:

• Neonatal Medicine
• Pediatric Cardiology
• Medical Diagnostics

Background:

• Patent ductus arteriosus (PDA) is a significant cause of morbidity in preterm infants, particularly those born before 28 weeks gestation.
• Clinical diagnosis of PDA in preterm infants is challenging due to nonspecific signs and symptoms, hindering early detection of significant shunting.
• Biomarkers like BNP and N-terminal pro-BNP are under investigation for PDA diagnosis.

Purpose of the Study:

• To review current diagnostic and therapeutic strategies for PDA in preterm infants.
• To evaluate the role of functional echocardiography in diagnosing hemodynamically significant PDA.
• To discuss the efficacy and potential adverse effects of pharmacological PDA closure.

Main Methods:

• Review of current literature on PDA diagnosis and management in preterm neonates.
• Discussion of the utility of functional echocardiography for bedside diagnosis.
• Analysis of pharmacological treatments, including cyclo-oxygenase inhibitors like ibuprofen and indomethacin.

Main Results:

• Functional echocardiography shows promise for early diagnosis of hemodynamically significant PDA, though standardized criteria are lacking.
• Pharmacological closure using cyclo-oxygenase inhibitors achieves 70-80% success rates; oral ibuprofen is a viable alternative in specific settings.
• Concerns exist regarding long-term benefits and potential adverse effects (e.g., ROP, BPD) of prophylactic PDA treatment.

Conclusions:

• Individualized treatment decisions for PDA should be based on clinical significance, considering gestation, birth weight, echocardiography, and clinical status.
• Further research is needed to establish long-term benefits and risks associated with PDA treatment strategies.
• Functional echocardiography is a valuable tool for guiding management, but universally accepted criteria for hemodynamic significance are still needed.